Lumacaftor is a CFTR modulator utilized primarily in combination therapies to improve protein folding and function for the treatment of cystic fibrosis. Accurate analytical analysis of this therapeutic… Read more
![Chemical structure of 1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(5-methyl-6-(3-pentanoylphenyl)pyridin-2-yl)cyclopropane-1-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2760759-54-2-1-22-Difluorobenzod13dioxol-5-yl-N-5-methyl-6-3-pentanoylphenylpyridin-2-ylcyclopropane-1-carboxamide.png&w=3840&q=75)
![Chemical structure of 1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(5-methylpyridin-2-yl)cyclopropane-1-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1189328-38-8-1-22-Difluorobenzod13dioxol-5-yl-N-5-methylpyridin-2-ylcyclopropane-1-carboxamide.png&w=3840&q=75)
![Chemical structure of 1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropane-1-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2071254-53-8-1-22-Difluorobenzod13dioxol-5-ylcyclopropane-1-carboxamide.png&w=3840&q=75)

![Chemical structure of 2-(3-Carboxyphenyl)-6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropane-1-carboxamido)-3-methylpyridine 1-oxide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2760759-52-0-2-3-Carboxyphenyl-6-1-22-difluorobenzod13dioxol-5-ylcyclopropane-1-carboxamido-3-methylpyridine-1-oxide.png&w=3840&q=75)
![Chemical structure of 3-(6-(3-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-5-hydroxy-2-oxopyrrolidin-1-yl)-3-methylpyridin-2-yl)benzoic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2732521-08-1-3-6-3-22-Difluorobenzod13dioxol-5-yl-5-hydroxy-2-oxopyrrolidin-1-yl-3-methylpyridin-2-ylbenzoic-Acid.png&w=3840&q=75)




![Chemical structure of N-(6-Chloro-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropane-1-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F936727-68-3-N-6-Chloro-5-methylpyridin-2-yl-1-22-difluorobenzod13dioxol-5-ylcyclopropane-1-carboxamide.png&w=3840&q=75)

Lumacaftor is a CFTR modulator utilized primarily in combination therapies to improve protein folding and function for the treatment of cystic fibrosis. Accurate analytical analysis of this therapeutic requires a comprehensive suite of high-quality compounds to ensure regulatory compliance and safety. This category provides essential reference standards for Lumacaftor, including pharmacopeial and non-pharmacopeial impurities, degradation products, and metabolites such as glucuronide conjugates. Pharmaceutical laboratories rely on these materials for rigorous impurity profiling and method validation throughout the drug development lifecycle. Additionally, stable isotope labelled compounds are available to serve as internal standards in mass spectrometry-based bioanalytical assays, facilitating precise quantification and pharmacokinetic studies. By utilizing these well-characterized materials, researchers can maintain the stringent quality control standards necessary to support the safe and effective production of this cystic fibrosis treatment.